ABSTRACT
With the advent of more effective therapies for human immunodeficiency virus (HIV) infection, HIV-positive patients are living symptom-free longer and leading more normal lives. However, new complications such as cardiovascular disease are becoming more prevalent in this population. Patients with HIV infection currently represent one of the most rapidly developing groups with cardiovascular disease globally. Moreover, the protease inhibitors (PIs) used to treat HIV infection induce a syndrome of lipodystrophy and dyslipidemia that may be associated with accelerated atherosclerosis as well as insulin resistance (1).
